Glycine receptors (GlyRs) are indispensable to maintain excitatory/inhibitory balance in neuronal circuits controlling reflex and rhythmic motor behaviors. Here we have developed Glyght, the first GlyR ligand controlled with light. It is selective over other cys-loop receptors, active in vivo, and displays an allosteric mechanism of action. The photomanipulation of glycinergic neurotransmission opens new avenues to understand inhibitory circuits in intact animals, and to develop drug-based phototherapies.
MAIN
The control of biological activity with light has become a powerful tool to understand complex multicellular 1 and intracellular processes 2 , protein dynamics 3, 4 , as well as to develop novel therapeutic strategies 4 . In particular, optogenetics 5 and photopharmacology 6 have been a boon for neurobiology, empowering it to control neuronal receptor activity with subtype pharmacological selectivity and micrometric resolution 7, 8 , firing individual neurons 9 and mapping their connectivity and strength 10 .
Photoswitchable ligands 6 enable directly controlling the activity of endogenous receptors without requiring genetic manipulation 8, 11 . They can be applied to intact tissue, making drug-based phototherapies possible. Despite the importance of inhibitory receptors, few photoswitches targeting ionotropic gamma amino butyric acid receptors (GABA A Rs) have been reported [12] [13] [14] [15] , and no specific modulator has been developed for glycine receptors (GlyRs).
GlyRs and GABA A Rs belong to the pentameric Cys-loop superfamily along with excitatory nicotinic acetylcholine (nAChRs) and serotonin receptors (5-HT 3 R).
GABA A Rs and GlyRs share not only the pentameric assembly of their subunits and the inhibitory regulation of cell membrane potential through their chloride-selective pore, but also the mechanism of agonist-induced desensitization, which is driven by homologous residues between transmembrane domains of the receptor 16 .These similarities hamper the development of selective ligands.
Alterations in inhibitory neurotransmission cause an excitation/inhibition disbalance that has been linked to many and etiologically diverse neurological diseases, from epilepsy to anxiety, autism 17 and schizophrenia 18 . Modulating neuronal inhibition with systemically administered drugs can partially restore balance and reduce certain symptoms, but the efficacy of these strategies is very limited in diseases where specific 5 circuits are altered. In these cases, what matters is the precise location and timing of inhibition to restore homeostasis, and cure is unlikely even with the most pharmacologically selective drugs.
In particular, glycinergic transmission regulates the majority of reflex and rhythmic motor behaviors, including locomotion and breathing 19 .Normal functioning of locomotor circuits relies on a strictly determined equilibrium between excitatory and inhibitory synapses onto interneurons 20 . Disruptions to this balance trigger locomotor dysfunctions 21 . Insufficient GlyR function leads to excessive startle response (hyperekplexia) and other pathologies 22, 23 . Despite the importance of glycinergic neurotransmission, the repertoire of GlyR drugs available is still extremely limited 24, 25 and not highly specific 26 . Strychnine and tropisetron remain the only modulators that show selectivity for GlyR over GABA A R, but the former is also nAChR antagonist 27, 28 , and the latter antagonizes 5-HT 3 R 29, 30 . Selective GlyR drugs are necessary to treat hyperekplexia, autism, chronic inflammatory pain, breathing disorders, temporal lobe epilepsy, alcoholism, and motor neuron disease 26 . However, given the diversity and ubiquity of glycinergic circuits, traditional pharmacology is unlikely to be enough unless the activity of these ligands can be modulated right at the specific circuits involved in every disease.
Here, we initially aimed at developing photoswitchable ligands of GABA A Rs based on benzodiazepines. Azo-compounds (3a-d, Figure 1a ) were thus designed to display cistrans photochromism while maintaining the ability of the nitrazepam moiety to bind the GABA A R, as reported for other substitutions at the same position of the ligand 31 .
Unexpectedly, we obtained a GlyR-selective negative allosteric modulator whose inhibitory action at GlyRs was increased under UV light (cis-on), and that we named Glyght (short for 'GlyR controlled by light').
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The photochromic azo moiety was introduced via a Mills reaction of several nitroso aryl moieties (compounds 1a-d, Figure 1a ) with the amino-substituted benzene in the structure of 7-aminonitrazepam (compound 2, Figure 1a , obtained as reported 32, 33 ). All derivatives reversibly photoswitch at 365 nm (trans to cis isomerization) and 455 to 530 nm (cis to transisomerization), as exemplarily shown for the pyridine-based derivative 3d (Glyght) (Figure 1b) . Thermal relaxation half-lives in the dark are longer than 1h (Supplementary Table 1 and Supplementary Figures 19-22) .
To characterize the photopharmacological effects of compounds 3a-d, we designed a behavioral assay to record and quantify the swimming activity of zebrafish larvae as a function of illumination. Zebrafish express all GABA A R and GlyR subunits, with high sequence similarity to the mammalian receptors 34 , and larvae display full exploratory capacities at 7 days post fertilization (dpf) [35] [36] [37] . Ligands of inhibitory receptors should alter the well known behavioural activity of the larvae, and be correlated to specific dynamic traits such as speed swimming variations, transition swimming patterns or anxiety-like behaviours 38, 39 .In order to identify alterations in inhibitory neurotransmission, we focused on fast movements and measured swimming distances and duration of high speed swimming 38, 40 .Individual larvae were placed in separate wells of a 96-well plate (Figure 1c In all cases, the time spent in fast swimming (see online Methods for details) is longer under UV than under visible light, but only for Glyght (3d) this difference is higher than for controls. In order to identify photoswitchable hits, we assumed larvae swimming activity as the quantifiable variable, and we defined light periods as intrinsically dependent variables of larvae behavioral outcomes. We calculated the ratio between the activities under UV and under visible light (UV/vis activity ratio, UVAR) and used it as a score to identify compounds producing photoswitchable behaviors. Three compounds displayed UVARs significantly different from the control (UVAR of endogenous photoresponses in vehicle, Supplementary Figure 1) . One was excluded due to precipitation over time (3c) and two were retained for further studies: 3b (azo-NZ1, a GABA A R blocker reported in a separate article 41 ), and 3d (Glyght) characterized below.
For Glyght, we confirmed the hit in 5 independent experiments from different larvae batches (Supplementary Figures 2 and 3) and verified that photoresponses are dosedependent (Figure 1e ) before moving on to in vitro pharmacological characterizations with an activity assay. Figure   4 ). UV light prevented the weak current inhibition of GABA A R by Glyght.
Since the action of Glyght on GABA A Rs cannot account for the robust behavioral effects observed in fish (Figure 1c-f) , we asked whether this compound might interact with other inhibitory ligand-gated receptors responsible for the control of movement 26, 43 , namely GlyR. Thus, we tested Glyght in zebrafish α 1 (α 1Z ) and Figure 5hi) . Importantly, these results were confirmed in mammalian GlyRs where Glyght caused strong cis-on inhibition in all homomeric and heteromeric receptors (α 1 , Figure 6cf) . Since Glyght displays selectivity for GlyRs compared to GABA A Rs (Figure 2c) , we further characterized its activity in other pentameric receptors. The compound displayed low activity and no photoswitching in 5-HT 3A R (Figure 2cand Supplementary Figure 7) and was completely inactive in muscular nAChR (Supplementary Figure 8) . Glyght binds preferentially at a non-glycine site located at the interface of the extracellular and transmembrane domains (ECD and TMD) that is involved in the allosteric coupling between ligand binding to the ECD and opening 12 of the ion channel pore in the TMD [44] [45] [46] [47] [48] .e, Detailed view of the intersubunit site at the ECD/TMD interface including the protein loops changing conformation upon receptor activation 49 Figure 9-10) . We focused on the latter binding site, since it is the region showing the largest differences in ligand pose densities for both α 1 Ζ and α 2 H GlyRs. Moreover, this site includes key residues for channel activation and conductance 50, 51 and is involved in allosteric coupling between ligand binding to the ECD and ion channel pore opening in the TMD [44] [45] [46] [47] [48] . As shown in We have used a zebrafish behavioral assay and photoresponse score to identify the first GlyR-selective, light-regulated inhibitor. Glyght loses inhibitory activity at saturating glycine concentrations, which is compatible with orthosteric or allosteric antagonism 53 (Supplementary Figure 5bcef) . Molecular modeling results indicate that Glyght binds to an allosteric site that regulates GlyR gating and conductance 44-48, 50, 51 (Figure 2de) .
Thus, Glyght also provides a template to design new allosteric non-photoswitchable ligands like amide, ether or methoxy analogs bearing general pharmacological interest.
Glyght reversibly elicits excitatory behaviors in zebrafish larvae and is a good candidate to study glycinergic neurotransmission in spatiotemporally defined patterns, and to explore therapeutic approaches based on localized and selective activation of GlyRs.
The partial activity of Glyght in 5-HT 3A Rs is consistent with tropisetron's effect in both receptors 30 and anticipates moderate emetic activity. However, its high selectivity with respect to nicotinic receptors makes Glyght remarkably superior to strychnine 27 , raising hopes to modulate GlyRs without concomitant toxicity and opening a new avenue to clinical pharmacology at large.
